How many stocks are there of SenzaGen?
The current number of stocks of SenzaGen is 24.19 M undefined.
SenzaGen Stocks 2024
SenzaGen Stocks
24.19 M
Ticker
SENZA.ST
ISIN
SE0010219626
WKN
A2DX79
In 2024, SenzaGen had 24.19 M outstanding stocks, a 0% change from the 24.19 M stocks in the previous year.
The SenzaGen Stocks history
| YEAR | NUMBER OF STOCKS (undefined SEK) |
|---|---|
| 2029e | 24.19 |
| 2028e | 24.19 |
| 2027e | 24.19 |
| 2026e | 24.19 |
| 2025e | 24.19 |
| 2024e | 24.19 |
| 2023 | 24.19 |
| 2022 | 24.09 |
| 2021 | 23.16 |
| 2020 | 21.36 |
| 2019 | 16.18 |
| 2018 | 15.91 |
| 2017 | 8.24 |
| 2016 | 11.09 |
| 2015 | 11.09 |
| 2014 | 5.38 |
SenzaGen shares outstanding SE0010219626 · A2DX79
The number of shares was SenzaGen in 2023 — This indicates how many shares 24.188 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue SenzaGen earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates SenzaGen's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of SenzaGen’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating SenzaGen's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2014 | 5.38 M Aktien |
| 2015 | 11.09 M Aktien |
| 2016 | 11.09 M Aktien |
| 2017 | 8.24 M Aktien |
| 2018 | 15.91 M Aktien |
| 2019 | 16.18 M Aktien |
| 2020 | 21.36 M Aktien |
| 2021 | 23.16 M Aktien |
| 2022 | 24.09 M Aktien |
| 2023 | 24.19 M Aktien |
| 2024e | 24.19 M Aktien |
| 2025e | 24.19 M Aktien |
| 2026e | 24.19 M Aktien |
| 2027e | 24.19 M Aktien |
| 2028e | 24.19 M Aktien |
| 2029e | 24.19 M Aktien |
SenzaGen Aktienanalyse
What does SenzaGen do?
SenzaGen AB is a Swedish biotechnology company that specializes in the development and marketing of innovative and reliable tests for assessing allergenicity. Founded in 2010 by leading experts from the academic and industry sectors, the company has become a significant player in the field of toxicology. Current methods for assessing allergenicity, such as asthma, eczema, and allergic reactions, are often inaccurate and require the use of animals, which is ethically questionable and expensive. SenzaGen AB has developed a wide range of tests based on biomolecular technologies that use human cells to assess the allergenic reactivity of chemicals and products. These tests are accurate, cost-effective, and meet the current requirements of regulatory authorities and the industry. The company is headquartered in Lund, Sweden, and currently employs about 20 people. SenzaGen AB is a leader in the development of in vitro methods for evaluating allergenicity and utilizes various platform technologies such as gene expression and proteomics analysis, as well as the use of immune cells and keratinocytes. SenzaGen AB's Microarray technology platform, based on DNA-based tests, has been recognized by the European Chemicals Agency (ECHA) as suitable for assessing allergenic reactivity. The company has also partnered with the US biotechnology company In vitro International (IVI) to distribute its allergen tests in the North American market. SenzaGen AB has developed a wide range of products that can be used in various sectors such as cosmetics, food, chemicals, and pharmaceuticals. AllergoDx™ is a test system used by the pharmaceutical and chemical industries to determine the allergenic reactivity of chemicals. GARD™ (Genomic Allergen Rapid Detection) is a rapid test used in the cosmetics and food industries to determine the allergenic reactivity of new products and avoid costly animal testing. GARDskin™ is a skin test used to determine the reactivity of substances that come into contact with the skin, primarily in the chemicals and pharmaceutical industries. Other products in the company's pipeline include GARDpotency™ and GARDair™, which are intended for assessing allergic reactions in industrial and occupational environments. SenzaGen AB has experienced significant growth in recent years and plans to expand its product range and strengthen its market position. The company's business model is based on selling tests and services to chemical, pharmaceutical, food, and cosmetic companies worldwide. Through its innovative technologies and willingness to collaborate with customers, the company has taken a leadership role in toxicology. SenzaGen AB is committed to an ethical and responsible corporate philosophy focused on sustainability and environmental protection. The company has clear goals to meet the growing demand for reliable and ethical testing methods to minimize the impact of chemicals on humans and the environment. SenzaGen ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating SenzaGen's Shares Outstanding
SenzaGen's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in SenzaGen’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding SenzaGen’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in SenzaGen’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about SenzaGen stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of SenzaGen are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of SenzaGen evolved in recent years?
The number of shares of SenzaGen has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. SenzaGen as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of SenzaGen?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does SenzaGen pay?
Over the past 12 months, SenzaGen paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, SenzaGen is expected to pay a dividend of 0 SEK.
What is the dividend yield of SenzaGen?
The current dividend yield of SenzaGen is .
When does SenzaGen pay dividends?
SenzaGen pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of SenzaGen?
SenzaGen paid dividends every year for the past 0 years.
What is the dividend of SenzaGen?
For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.
In which sector is SenzaGen located?
SenzaGen is assigned to the 'Health' sector.
Wann musste ich die Aktien von SenzaGen kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of SenzaGen from 11/5/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 11/5/2024.
When did SenzaGen pay the last dividend?
The last dividend was paid out on 11/5/2024.
What was the dividend of SenzaGen in the year 2023?
In the year 2023, SenzaGen distributed 0 SEK as dividends.
In which currency does SenzaGen pay out the dividend?
The dividends of SenzaGen are distributed in SEK.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von SenzaGen
Our stock analysis for SenzaGen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SenzaGen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
